<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>abdominal adiposity</td>
<td>124</td>
</tr>
<tr>
<td>acute coronary syndrome (ACS)</td>
<td>4–5, 19</td>
</tr>
<tr>
<td>acute heart failure</td>
<td>6–8</td>
</tr>
<tr>
<td>acute psychological risk factors</td>
<td>1, 2</td>
</tr>
<tr>
<td>alcohol abuse</td>
<td>52–3</td>
</tr>
<tr>
<td>co-occurrence with CVD</td>
<td>233–4</td>
</tr>
<tr>
<td>alprazolam</td>
<td></td>
</tr>
<tr>
<td>drug interactions</td>
<td>207, 208</td>
</tr>
<tr>
<td>ambrisentan</td>
<td>90</td>
</tr>
<tr>
<td>amiodarone</td>
<td>52, 206</td>
</tr>
<tr>
<td>drug interactions</td>
<td>207, 210</td>
</tr>
<tr>
<td>amitriptyline</td>
<td>199</td>
</tr>
<tr>
<td>drug interactions</td>
<td>207</td>
</tr>
<tr>
<td>amphetamines and CVD</td>
<td>234</td>
</tr>
<tr>
<td>anger</td>
<td>5</td>
</tr>
<tr>
<td>angina, Prinzmetal’s</td>
<td>4</td>
</tr>
<tr>
<td>angiotensin receptor blockers</td>
<td>125</td>
</tr>
<tr>
<td>angiotensin-converting enzyme (ACE) inhibitors</td>
<td>52, 125</td>
</tr>
<tr>
<td>psychiatric effects</td>
<td>202</td>
</tr>
<tr>
<td>anhedonia</td>
<td>35</td>
</tr>
<tr>
<td>antidepressants</td>
<td></td>
</tr>
<tr>
<td>1st generation</td>
<td>72–3</td>
</tr>
<tr>
<td>2nd generation</td>
<td>73</td>
</tr>
<tr>
<td>3rd generation</td>
<td>73–4</td>
</tr>
<tr>
<td>anxiety</td>
<td></td>
</tr>
<tr>
<td>behavior lifestyle changes</td>
<td>129</td>
</tr>
<tr>
<td>cardiac transplant</td>
<td>67</td>
</tr>
<tr>
<td>cardiovascular manifestations</td>
<td>167, 173–5</td>
</tr>
<tr>
<td>cardiac symptoms and cardiophobia</td>
<td>169</td>
</tr>
<tr>
<td>comorbidity and differential diagnosis</td>
<td>169–70</td>
</tr>
<tr>
<td>decision matrix</td>
<td>174</td>
</tr>
<tr>
<td>functional analysis</td>
<td>170</td>
</tr>
<tr>
<td>implantable cardioverter defibrillator (ICD)</td>
<td>171–3</td>
</tr>
<tr>
<td>pathophysiology of emotions</td>
<td>167–9</td>
</tr>
<tr>
<td>treatment considerations</td>
<td>170–1</td>
</tr>
<tr>
<td>hypertrophic cardiomyopathy (HCM)</td>
<td>108</td>
</tr>
<tr>
<td>non-cardiac chest pain (NCCP)</td>
<td>100–1</td>
</tr>
<tr>
<td>fear-avoidance model</td>
<td>102</td>
</tr>
<tr>
<td>aortic valve replacement</td>
<td>50–1</td>
</tr>
<tr>
<td>Apnea/Hypopnea Index (AHI)</td>
<td>143–4</td>
</tr>
<tr>
<td>aripiprazole</td>
<td>121</td>
</tr>
<tr>
<td>metabolic complications</td>
<td>197, 198</td>
</tr>
<tr>
<td>QT prolongation</td>
<td>198</td>
</tr>
<tr>
<td>arrhythmias</td>
<td>3, 5–6</td>
</tr>
<tr>
<td>sleep apnea</td>
<td></td>
</tr>
<tr>
<td>effect of OSA treatment</td>
<td>149–50</td>
</tr>
<tr>
<td>pathophysiology</td>
<td>148–9</td>
</tr>
<tr>
<td>prevalence</td>
<td>148</td>
</tr>
<tr>
<td>asenapine</td>
<td></td>
</tr>
<tr>
<td>metabolic complications</td>
<td>197</td>
</tr>
<tr>
<td>QT prolongation</td>
<td>198</td>
</tr>
<tr>
<td>aspirin</td>
<td>26, 52, 206</td>
</tr>
<tr>
<td>asymmetric dimethyl arginine (ADMA)</td>
<td>40</td>
</tr>
<tr>
<td>atheroma of ascending aorta</td>
<td>54</td>
</tr>
<tr>
<td>atherosclerosis</td>
<td>18–19</td>
</tr>
<tr>
<td>atorvastatin</td>
<td></td>
</tr>
<tr>
<td>US expenditure</td>
<td>213</td>
</tr>
<tr>
<td>atrial fibrillation</td>
<td>150</td>
</tr>
<tr>
<td>automatic external defibrillators (AEDs)</td>
<td>78</td>
</tr>
</tbody>
</table>

autonomic nervous system dysregulation 11–12, 22–3, 80
autopoietic cycle 101

bariatric surgery 125
Benson’s Relaxation Response 224–5
benzodiazepines 74

panic attacks 171
pulmonary artery hypertension, 92
beta-blockers 125
hypertrophic cardiomyopathy (HCM) 107
psychiatric effects 201–2

Bipolar Collaborative Care Model (BCCM) 127
bipolar disorder 116–17, 131

cardiovascular disorders
 premature mortality 119
risk 119–20
diagnosis 122–5
risk management protocol, European 123
screening criteria 124
mechanisms leading to increased CVD risk
medications 121
psychopharmacologic treatments and cardiometabolic risk 120
undertreatment 122–3
unhealthy behaviors 120
overview 117–18
bipolar I and II 118
epidemiology 118
inadequate screening and undertreatment 118–19
treatment, non-pharmacologic 125–6
collaborative care models (CCMs) 126–7
coordination to improve health outcomes 126
effectiveness of Chronic Care Model 127
Life Goals Collaborative Care (LGCC) 127–31
treatment, pharmacologic 125

blood pressure, elevated 124
bosentan 90
brain natriuretic peptide (BNP) 40
Brugada syndrome 77
buprenorphine
 drug interactions 207
bupropion 27, 73, 125, 199
 drug interactions 203, 209
Buspirone
 pulmonary artery hypertension 92
calcium channel blockers 125
psychiatric effects 202
cannabis usage and CVD 234
captopril 56, 202
carbamazepine 121, 199
drug interactions 203, 208, 209
cardiac and somatic symptoms, distinguishing between 99–100, 102–3
medically unexplained symptoms (MUS) 101–2
psychiatric disorders 100–1

cardiac arrest, sudden see sudden cardiac arrest (SCA)
cardiac surgery 49
congenital heart disease (CHD) 58–9
intra-operative period 54
atheroma of ascending aorta 54
blood pressure 54
cardiopulmonary bypass (CPB) 54
gaseous micro bubbles 54–5
valve surgery 55
postoperative period
cognition 55–6
delirium 56–7
depression 57–8
health-related quality of life 58
pre-operative period 49–50
compliance 53–4
delirium risk factors 50
depression and anxiety disorders 50–1
psychotropic medications 51–2
substance abuse 52–3
cardiac transplantation 62, 75
background 62–5
post-transplant psychiatric care 70–1
psychiatric comorbidity 71
psychiatric diagnosis 71
treatment 71–5
pre-transplant assessment 65
psychiatric comorbidity 65–7
screening and management 67–8
cardiophobia 169
cardiopulmonary bypass (CPB) 54
cardiovascular disease (CVD)
depression 18, 29–30
clinical considerations 26–9
epidemiology 19–21
possible mechanisms 21–4
risk factors for CAD pathogenesis 24–5
treatment 25–6
diagnostic screening criteria 124
future directions 12–14
molecular relationships between depression, inflammation and CVD 185–6
coronary artery disease (CAD) (Continued)
potential pathways predisposing to both
depression and CAD 179
serotonergic pathway 179–81
psychological distress 1
conceptual model 2
definition 2–3
stress-related mechanisms as a risk factor for both
depression and CAD 181–3
cortisol 22
C-reactive protein (CRP) 23
cyclothymia 118
cytokines 40–1, 184–6
delirium, post-operative 49, 56–7
risk factors 50
depression
behavior lifestyle changes 129
beta blockers 201
cardiac surgery 50–1
cardiac transplant 66–7
evidence for genetic vulnerability to
CAD 177–8
exercise see exercise and depression
healthy and at-risk populations 212
heart failure 34–5, 45–6
course and prognosis 39–40
diagnosis 35–6
incidence and prevalence 36–9
pathophysiology 40–3
treatment 43–5
links with cardiovascular disease (CVD) 8–10, 18, 29–30
clinical considerations 26–9
epidemiology 19–21
possible mechanisms 21–4
risk factors for CAD pathogenesis 24–5
treatment 25–6
methyldopa 202–3
molecular relationships between CAD,
immunology and psychiatric illness
cytokines and inflammation 184–6
inflammation and CVD 185–6
pulmonary artery hypertension 92
pathophysiology of CVD 213–14
patient health questionnaire (PHQ-9) 212
potential pathways predisposing to both
depression and CAD 179
serotonergic pathway 179–81
presentation in cardiac patients vs psychiatric
patients 9
stress-related mechanisms as a risk factor for both
depression and CAD 181–3
sudden cardiac arrest (SCA) 79
desipramine
drug interactions 207
dexmedetomidine 56
diabetes 22, 124
diazepam
drug interactions 208
diet 21–2
digoxin 56, 206
drug interactions 205
diltiazem
drug interactions 205, 208, 210
disopyramide 206
diuretics 202
divalproex 121
Do Not Resuscitate – Do Not Intubate (DNR-DNI)
requests 82
doxazosin 202
doxepin
drug interactions 207
drug interactions see pharmacological effects and
drug interactions
duloxetine 199
electroconvulsive therapy (ECT) 75
emotions and depression 24
episodic psychological risk factors 1, 2, 8–10
epoprostenol 90
escitalopram 44
escitalopram 209
exercise and depression 21–2, 211–12, 220
effect on cardiovascular physiology 214–15
risk factor in depression 216–17
exercise as therapy 217–18
exercise prescription 218–19
maintaining compliance 219
future directions 219–20
salutary effects 219
exhaustion, links with cardiovascular disease
(CVD) 8–10
ezetimibe
US expenditure 213
familial pulmonary artery hypertension (FPAH) 89
fatigue 201–2
links with cardiovascular disease (CVD) 10
fear-avoidance model for NCCP 102
felodipine
  drug interactions 203
flecainide 206
  drug interactions 203
fluoxetine 44
  drug interactions 203–4, 209
    PTSD 159
fluvoxamine
  drug interactions 204, 209
furosemide 51–2, 56
gaseous micro bubbles 54–5
genetic effects 24
genetic susceptibility 176, 186–8
epidemiologic review 176–7
evidence for depression and CAD 177–8
molecular relationships between CAD, immunology and psychiatric illness depression, cytokines and inflammation 184–6
depression, inflammation and CVD 185–6
potential pathways predisposing to both depression and CAD 179
serotonergic pathway 179–81
stress-related mechanisms as a risk factor for both depression and CAD 181–3
genetic testing, psychiatric issues 110–11
haloperidol 56, 121
  metabolic complications 197
  QT prolongation 198
health-related quality of life (HRQoL) 58
heart block 149
heart rate variability (HRV) 23
high density lipoprotein (HDL) 19, 124
high intensity transient signals (HITS) 54–5
hostility 11
hydralazine 202
hydrochlorothiazide 56
hypersomnia
  risk factors 142
hypertension 124
obstructive sleep apnea (OSA) 144–5
  pathophysiologic mechanisms 145
hypertrophic cardiomyopathy (HCM) 106, 112–13
  overview 106–8
psychiatric issues with genetic testing 110–11
psychiatric morbidities 108–9
quality of life 109–10
hypothalamic–pituitary–adrenal (HPA) axis 22
hypoxic sleep-disordered breathing 140–1
idiopathic pulmonary artery hypertension (IPAH) 89
iloperidone
  metabolic complications 197
  QT prolongation 198
iloprost 90
imipramine
  drug interactions 207
Impact of Events Scale 157
implantable cardioverter defibrillators (ICDs) 78, 85
  panic attacks 171–3
  psychiatric consequences 83–5
PTSD 171–2
inflammation
  molecular relationships between CAD, immunology and psychiatric illness depression and cytokines 184–6
depression, inflammation and CVD 185–6
psychological distress 12
insomnia 135–6
  cardiovascular disease 138–9
  overview 137–8
  risk factors 142
interleukin-10 40
Interpersonal Psychotherapy (IPT) 92, 95
lamotrigine 121
learned helplessness 171
left ventricular assist devices (LVADs) 62, 68–70
lidocaine 206
Life Goals Collaborative Care (LGCC) 127
  behavior lifestyle changes 129–30
  care management 130
  community settings 131
  decision support 130
  self-management 128, 130
lipid levels 124
lisinopril 202
lithium 52, 74–5, 121, 199
long-QT syndrome 77
loving-kindness meditation (LKM) 227–8
low density lipoprotein (LDL) 19, 124
major depressive disorder (MDD) 20
  see also depression
  congestive heart failure (CHF) 35–6
  inflammatory cytokines 40
mania, behavior lifestyle changes 129
mantra-based meditations 224
medically unexplained symptoms (MUS) 101–2
meditation 223, 228–9
clinical vignette 228
concentration modalities
empirical findings 225
overview 224–5
contemplation modalities 227–8
definitions 223–4
mindfulness modalities
empirical findings 226–7
overview 225–6
mental stress 4
mesoridazine 200
metabolic syndrome 22, 181
123I-meta-iodo-benzyl-guanidine (MIBG) 169
metformin 125
methyl dopa 202–3
metoprolol
drug interactions 203, 204, 205
mexiletine 206
drug interactions 203, 204
midazolam 56
migraine 4
mindfulness meditation 224
empirical findings 226–7
overview 225–6
Mindfulness-Based Cognitive Therapy (MBCT) 226, 227
Mindfulness-Based Stress Reduction (MBSR) 225, 226, 227
mirtazapine 74, 199
drug interactions 207
mitral valve replacement (MVR) surgery 51, 53–4
postoperative cognition 55
mixed episodes 118
monoamine oxidase inhibitors (MAOIs) 72–3
myocardial infarction (MI) 4
depression 212
PTSD 153
assessment 156–8
consequences 155
predictors 156
prevalence 154–5
psychological treatment 160–1
myocardial ischemia 5
myocyte-specific enhancer factor-2A (MEF2A) gene 178
narcotics and CVD 234–5
nefazodone 44
neurohormonal activation 11–12
nifedipine 56
nitrates 202
nitric oxide (NO) 40
L-N-nitroarginine methyl ester (LNAME) 42
nocturnal polysomnography (NPSG) 142–3
atrial fibrillation 150
heart block 149
ventricular tachycardia 151
non-cardiac chest pain (NCCP) 4, 100–1
fear-avoidance model 102
non-REM sleep 136–7
nortriptyline 44, 73
drug interactions 207
obesity 21–2, 124
obstructive sleep apnea (OSA) 136, 139–41
arrhythmias
effect of OSA treatment 149–50
pathophysiology 148–9
prevalence 148
coronary artery disease 146
hypertension 144–5
other risk factors 145–6
heart failure
effect of OSA treatment 148
pathophysiology 147–8
prevalence 147
myocardial infarction 146
pulmonary hypertension
effect of OSA treatment 147
prevalence and severity 146–7
risk factors 142
signs and symptoms 142
treatment and prognosis 144
olanzapine 121
drug interactions 207
metabolic complications 197, 198
QT prolongation 198
olanzapine–fluoxetine 121
opiate dependency 53
paliperidone
QT prolongation 198
metabolic complications 197
palpitations 168–9
panic attacks 91
autonomic symptoms 169
cardiovascular manifestations 167, 173–5
cardiac symptoms and cardiophobia 169
comorbidity and differential diagnosis 169–70
Index

<table>
<thead>
<tr>
<th>255</th>
<th>decision matrix 174</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>implantable cardioverter defibrillator (ICD) 171–3</td>
</tr>
<tr>
<td></td>
<td>pathophysiology of emotions 167–9</td>
</tr>
<tr>
<td></td>
<td>treatment considerations 170–1</td>
</tr>
<tr>
<td></td>
<td>Panic Control Treatment 161</td>
</tr>
<tr>
<td></td>
<td>paroxetine 44</td>
</tr>
<tr>
<td></td>
<td>drug interactions 204–5, 209</td>
</tr>
<tr>
<td></td>
<td>PTSD 159</td>
</tr>
<tr>
<td></td>
<td>paroxysmal supraventricular tachycardia (PVST) 170</td>
</tr>
<tr>
<td></td>
<td>perphenazine</td>
</tr>
<tr>
<td></td>
<td>metabolic complications 197</td>
</tr>
<tr>
<td></td>
<td>personality traits</td>
</tr>
<tr>
<td></td>
<td>depression 24</td>
</tr>
<tr>
<td></td>
<td>links with cardiovascular disease (CVD) 10–11</td>
</tr>
<tr>
<td></td>
<td>pharmacological effects and drug interactions 196, 210</td>
</tr>
<tr>
<td></td>
<td>antidepressants</td>
</tr>
<tr>
<td></td>
<td>metabolic complications 199</td>
</tr>
<tr>
<td></td>
<td>QT prolongation 199</td>
</tr>
<tr>
<td></td>
<td>antipsychotics</td>
</tr>
<tr>
<td></td>
<td>metabolic complications 197–8</td>
</tr>
<tr>
<td></td>
<td>QT prolongation and sudden death 198–9</td>
</tr>
<tr>
<td></td>
<td>cardiac drugs 210</td>
</tr>
<tr>
<td></td>
<td>inhibitors 210</td>
</tr>
<tr>
<td></td>
<td>cardiac drugs interacting with psychotropic drugs 207–8</td>
</tr>
<tr>
<td></td>
<td>cardiovascular drugs 206</td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors 202</td>
</tr>
<tr>
<td></td>
<td>antiarrhythmics 206</td>
</tr>
<tr>
<td></td>
<td>antiplatelet agents and anticoagulants 206</td>
</tr>
<tr>
<td></td>
<td>beta blockers 201–2</td>
</tr>
<tr>
<td></td>
<td>calcium channel blockers 202</td>
</tr>
<tr>
<td></td>
<td>centrally acting agents 202–5</td>
</tr>
<tr>
<td></td>
<td>diuretics 202</td>
</tr>
<tr>
<td></td>
<td>lipid-lowering agents 206</td>
</tr>
<tr>
<td></td>
<td>peripherally acting agents 202</td>
</tr>
<tr>
<td></td>
<td>cardiovascular effects of psychoactive medications 196–7</td>
</tr>
<tr>
<td></td>
<td>commonly used drugs 208–9</td>
</tr>
<tr>
<td></td>
<td>minimizing cardiac risks 200–1</td>
</tr>
<tr>
<td></td>
<td>mood stabilizers</td>
</tr>
<tr>
<td></td>
<td>cardiac conduction 199</td>
</tr>
<tr>
<td></td>
<td>metabolic complications 199</td>
</tr>
<tr>
<td></td>
<td>psychiatric effects of cardiovascular medications 201</td>
</tr>
<tr>
<td></td>
<td>psychotropic drugs</td>
</tr>
<tr>
<td></td>
<td>inducers 209–10</td>
</tr>
<tr>
<td></td>
<td>inhibitors 209</td>
</tr>
<tr>
<td></td>
<td>psychotropic drugs interacting with cardiac drugs 203–5</td>
</tr>
<tr>
<td></td>
<td>phenelzine 199</td>
</tr>
<tr>
<td></td>
<td>phobic anxiety</td>
</tr>
<tr>
<td></td>
<td>sudden cardiac arrest (SCA) 79–80</td>
</tr>
<tr>
<td></td>
<td>pimozide 200</td>
</tr>
<tr>
<td></td>
<td>drug interactions 207, 208</td>
</tr>
<tr>
<td></td>
<td>platelets 23</td>
</tr>
<tr>
<td></td>
<td>positive airway pressure (PAP) 144</td>
</tr>
<tr>
<td></td>
<td>post-traumatic stress disorder (PTSD) 11, 81, 84, 153, 161</td>
</tr>
<tr>
<td></td>
<td>assessment in cardiac patients 156–8</td>
</tr>
<tr>
<td></td>
<td>consequences in coronary heart disease 155</td>
</tr>
<tr>
<td></td>
<td>diagnosis 153–4</td>
</tr>
<tr>
<td></td>
<td>ICD patients 171–2</td>
</tr>
<tr>
<td></td>
<td>pharmacologic treatment in cardiac patients 158–9</td>
</tr>
<tr>
<td></td>
<td>predictors in cardiac patients 156</td>
</tr>
<tr>
<td></td>
<td>prevalence and course in cardiac populations 154–5</td>
</tr>
<tr>
<td></td>
<td>psychological treatment in cardiac patients 159–61</td>
</tr>
<tr>
<td></td>
<td>prazosin 202</td>
</tr>
<tr>
<td></td>
<td>Prinzmetal’s angina 4</td>
</tr>
<tr>
<td></td>
<td>procaainamide 206</td>
</tr>
<tr>
<td></td>
<td>propafenone 206</td>
</tr>
<tr>
<td></td>
<td>drug interactions 203, 204, 205, 208, 210</td>
</tr>
<tr>
<td></td>
<td>propofol 56</td>
</tr>
<tr>
<td></td>
<td>propranolol</td>
</tr>
<tr>
<td></td>
<td>drug interactions 203, 204</td>
</tr>
<tr>
<td></td>
<td>protriptyline</td>
</tr>
<tr>
<td></td>
<td>drug interactions 207</td>
</tr>
<tr>
<td></td>
<td>psychological distress</td>
</tr>
<tr>
<td></td>
<td>biological pathways to cardiovascular risk 11</td>
</tr>
<tr>
<td></td>
<td>inflammation 12</td>
</tr>
<tr>
<td></td>
<td>neurohormonal activation and autonomic nervous system dysregulation 11–12</td>
</tr>
<tr>
<td></td>
<td>definition 2–3</td>
</tr>
<tr>
<td></td>
<td>future directions 12–14</td>
</tr>
<tr>
<td></td>
<td>links with cardiovascular disease (CVD) 1–2, 3–4</td>
</tr>
<tr>
<td></td>
<td>acute coronary syndrome (ACS)s 4–5</td>
</tr>
<tr>
<td></td>
<td>acute heart failure and Takotsubo syndrome 6–8</td>
</tr>
<tr>
<td></td>
<td>cardiac arrhythmias 5–6</td>
</tr>
<tr>
<td></td>
<td>conceptual model 2</td>
</tr>
<tr>
<td></td>
<td>episodic factors 8–10</td>
</tr>
<tr>
<td></td>
<td>myocardial ischemia 5</td>
</tr>
<tr>
<td></td>
<td>personality traits and socioenvironmental factors 10–11</td>
</tr>
<tr>
<td></td>
<td>triggering cardiac events 4</td>
</tr>
</tbody>
</table>
psychosis
  behavior lifestyle changes  129–30
psychotherapy  75
PTSD Symptom Scale-Self-Report (PSS-SR)  157
pulmonary artery hypertension (PAH)  88, 96
  biomedical aspects  88–90
    classification  89
    survival  89–90
    emotional adjustment  90–1
    psychiatric treatment  92–6
pulmonary hypertension (PH)  88–9
  effect of OSA treatment  147
  prevalence and severity  146–7
QT prolongation  196, 198–9
QT variability  6
quetiapine  56, 121
  drug interactions  207, 208
  metabolic complications  197
QT prolongation  198
quinidine  206
  drug interactions  204
Raynaud’s disease  4
REM sleep  136–7
resuscitation, (CPR) psychiatric
  consequences  81–3
risperidone  121
  drug interactions  208
  metabolic complications  197
QT prolongation  198
rosuvastatin
schizophrenia
  cardiac surgery  52
selective noradrenergic reuptake inhibitors
  (SNRIs)
  pulmonary artery hypertension  92
selective serotonin reuptake inhibitors
  (SSRIs)  73–4
PTSD  159
pulmonary artery hypertension  92
sexual dysfunction  43, 94
serotonergic pathway predisposing to both
depression and CAD  179
serotonin receptors  181
serotonin transporter polymorphism  179–81
tryptophan hydroxylase 2 and metabolic
  syndrome  181
sertraline  26, 27, 44
  cardiac transplant  74
drug interactions  205, 209
PTSD  159
sexual dysfunction  43
pulmonary artery hypertension  94
sildenafil  90
simvastatin
US expenditure  213
sleep and cardiovascular health  135, 150–1
hemodynamics during normal sleep  136–7
hypersomnia
  risk factors  142
insomnia  135–6
  cardiovascular disease  138–9, 139
  overview  137–8
  risk factors  142
sleep-related breathing disorders  139
  arrhythmias  148–50
  central sleep apnea (CSA)  141–2
  coronary artery disease and myocardial
  infarction  146
  coronary risk factors  144–6
  diagnosis  142–4
  heart failure  147–8
  obstructive sleep apnea (OSA)  136, 139–41,
  142
  pulmonary hypertension  146–7
  treatment and prognosis  144
smoking  21–2
  cardiac surgery  53
  co-occurrence with CVD  232–3
socioenvironmental factors
  depression  23–4
  social isolation  24
  links with cardiovascular disease (CVD)  10–11
sotalol  52
St John’s Wort  75
  drug interactions  205, 209–10
stimulants and CVD  234
stress  2
  early life stress  23–4
stressors  3, 4
Structured Clinical Interview for Diagnosis
  (SCID)  157
sudden cardiac arrest (SCA)  77–8, 85
  psychiatric contributions  78–81
sudden cardiac death (SCD)  106, 110
sympathetic adrenomedullary (SAM)
  activation  11–12
tacrolimus  73–4, 75
Takotsubo syndrome  6–8
thioridazine
    drug interactions 207
    QT prolongation 198

timolol
    drug interactions 203, 204, 205
torsade de pointes (TdP) 196

Transcendental Meditation (TM)
    224, 225

transplantation see cardiac transplantation

trazodone 73, 199

triazolam
    drug interactions 207, 208
tricyclic antidepressants (TCAs) 72–3
    pulmonary artery hypertension 92
    sexual dysfunction 43

triglycerides 124

trimipramine 207

trypophan hydroxylase 2 (TPH2)
    181

tumor necrosis factor-alpha (TNF-alpha)
    40

T-wave alternans 6

Type A personality 11

Type D personality 11
depression 24

valproic acid 199

valsartan
    US expenditure 213

valve surgery 55

varenicline 125

variant angina 4

venlafaxine 28, 199
    drug interactions 208
    US expenditure 213

ventricular tachycardia 151

verapamil 107
    drug interactions 205, 208, 210

vital exhaustion 10, 138

warfarin 56
    drug interactions 203, 204, 205

weight gain 197

ziprasidone 121
    metabolic complications 197, 198
    QT prolongation 198